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Abstract
Neural transplantation offers the potential of treating Parkinson’s disease by grafting fetal dopamine
neurons to depleted regions of the brain. However, clinical studies of neural grafting in Parkinson’s
disease have produced only modest improvements. One of the main reasons for this is the low survival
rate of transplanted neurons. The inadequate supply of critical neurotrophic factors in the adult brain
is likely to be a major cause of early cell death and restricted outgrowth of fetal grafts placed into
the mature striatum. Glial derived neurotrophic factor (GDNF) is a potent neurotrophic factor that
is crucial to the survival, outgrowth and maintenance of dopamine neurons, and so is a candidate for
protecting grafted fetal dopamine neurons in the adult brain. We found that implantation of adeno-
associated virus type 2 encoding GDNF (AAV2-GDNF) in the normal monkey caudate nucleus
induced over-expression of GDNF that persisted for at least 6 months after injection. In a 6-month
within-animal controlled study, AAV2-GDNF enhanced the survival of fetal dopamine neurons by
4-fold, and increased the outgrowth of grafted fetal dopamine neurons by almost 3-fold in the caudate
nucleus of MPTP-treated monkeys, compared with control grafts in the other caudate nucleus. Thus,
the addition of GDNF gene therapy to neural transplantation may be a useful strategy to improve
treatment for Parkinson’s disease.
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Neural transplantation offers the potential of treating Parkinson’s disease by grafting fetal
dopamine (DA) neurons to depleted regions of the host brain, providing those DA-deficient
regions with a regulated source of DA. This strategy promises to provide long-term
amelioration of parkinsonian signs, which available treatments are unable to achieve. Animal
studies in the rodent (reviewed by Brundin et al., 1994), and in the primate (Annett, 1994;
Bankiewicz et al., 1993; Elsworth et al., 1996; Fine et al., 1988; Taylor et al., 1991) have shown
that grafts of fetal DA neurons can lead to reversals in biochemical and behavioral indices of
DA deficiency. However, in clinical studies the improvements in Parkinsonism have been
variable, and generally rather modest (Freed et al., 1992; Freed et al., 2001; Lindvall and Hagell,
2001; Olanow et al., 2003; Redmond, 2002; Spencer et al., 1992; Widner et al., 1992).
The death of the majority (~90–95%) of transplanted DA neurons from the fetal ventral
mesencephalon (VM) soon after grafting in rat (Brundin et al., 2000) and human (Olanow et
al., 1996) can serve to limit the success of the neural transplantation treatment strategy for
Parkinson’s disease. An important contributor to this poor survival appears to be the
environment of the adult host brain, which may be less than optimal for the survival and growth
of grafted immature neurons. In particular, the inadequacy of critical growth factors in the adult
brain may be a major cause of early cell death and restricted outgrowth of fetal grafts placed
into the mature striatum. Thus, providing additional neurotrophic support for donor fetal
neurons may reduce the problem of poor survival of neural grafts in Parkinson’s disease.
Glial derived neurotrophic factor (GDNF) is a potent neurotrophic factor that is crucial to the
development, survival, and outgrowth of DA neurons (Airaksinen and Saarma, 2002; Lin et
al., 1993), and so it is a good candidate for protecting and maintaining grafted fetal DA neurons
in the host brain. GDNF is highly expressed in the developing rat striatum, yet its concentration
is relatively low in the adult brain (Choi-Lundberg and Bohn, 1995; Schaar et al., 1993;
Stromberg et al., 1993). Several studies in the 6-hydroxydopamine (6-OHDA) lesioned
striatum of rats have demonstrated improvements in survival and outgrowth of grafted fetal
DA neurons when central injections of GDNF have been administered, or when GDNF
overexpressing cells have been co-grafted to the striatum (Ahn et al., 2005; Espejo et al.,
2000; Rosenblad et al., 1996; Sautter et al., 1998; Sinclair et al., 1996; Sullivan et al., 1998;
Wilby et al., 1999; Yurek, 1998). These effects of GDNF on grafted VM were evaluated 1 to
8 weeks after transplantation. Gene therapy with a recombinant adeno-associated virus offers
a strategy for longer-term delivery of GDNF to circumscribed regions of the brain in a relatively
safe and non-invasive manner (Grieger and Samulski, 2005).
Interestingly in the rodent overexpression of GDNF in the intact striatum leads to an initial
increase in DA turnover, followed by a selective down-regulation of TH at times longer than
6 weeks (Georgievska et al., 2004b). However, in this rat study the effect on TH was not
accompanied by alteration in DA synthesis or content, indicating that the GDNF-induced
changes in TH are a compensation for the initial overactivity of the DA system. Likewise in
rats with a lesioned nigrostriatal DA system and intrastriatal grafts of fetal dopaminergic
neurons, overexpression of GDNF results in an increase in survival of fetal dopaminergic
neurons at 4 weeks, with an eventual down-regulation of TH in the grafted neurons
(Georgievska et al., 2004a). Despite these rodent data with lentivirus vector delivery of GDNF,
we were sufficiently encouraged by our studies with recombinant adeno-associated viral
vectors (AAV) (Sondhi et al., 2005) and with GDNF-secreting macrocapsules (Redmond et
al., 2002) to investigate the potential enhancement of fetal DA neuron survival and outgrowth
in the striatum of MPTP-treated monkeys co-implanted with a recombinant AAV harboring
the GDNF gene.
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Young adult male St Kitts green (vervet) monkeys (Chlorocebus sabaeus) at the St Kitts
Biomedical Research Foundation (St. Kitts, West Indies) were used. As the subjects were feral
monkeys, their exact ages were not known, but they were all mature with a mean weight (±
standard deviation) of 6.4 ± 0.6 kg. All studies were conducted in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by
the Institutional Animal Care & Use Committee.
Striatal delivery of GDNF by AAV2-GDNF in normal monkeys
Production and purification of recombinant AAV serotype 2 vector (AAV2) is described
elsewhere (Grieger et al., 2006). For the present study, the vector plasmid contained the human
GDNF cDNA, driven by a chicken beta-actin promoter with a cytomegalovirus immediate-
early enhancer, flanked by AAV2 inverted terminal repeats (Fig. 1). The head of the right
caudate nucleus of 10 monkeys was injected by stereotactic surgery with 12 microliters of
AAV2-GDNF at a concentration of 2.3 × 109 particles per microliter, delivered at 1 microliter
per minute by a microperfusion pump (Stoelting Instruments, Wood Dalle, IL). Animals were
euthanized by pentobarbital overdose at 1 month (mean time ± S.D., 36 ± 1 day), 3 months (95
± 4 days) or 6 months (185 ± 4 days) after treatment. Brains were perfused with saline, followed
by 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4), as before (Sladek et al., 1995).
After postfixing overnight, brains were stored in 0.1M phosphate buffer containing 0.1%
sodium azide (pH 7.4). Subsequently, 50 micrometer-thick serial Vibratome sections were cut
coronally through the caudate nucleus. Every fourth section was double-labeled for GDNF-
immunoreactivity, using goat anti-GDNF (BAF-212 at 1:250, R&D Systems, Minneapolis,
MN). GDNF-immunoreactivity was visualized using biotinylated horse anti-goat IgG
(BA-9500 at 1:250, Vector Laboratories, Burlingame, CA), and the ABC technique with
nickel-intensified 3,3′-diaminobenzidine (DAB) as chromagen. Quantification comprised
unbiased stereological counts of GDNF-ir cells in the caudate nucleus together with the volume
of tissue occupied by GDNF-ir. These measures were made using StereoInvestigator 7 software
(MicroBrightField Inc., Williston, VT).
Implantation of AAV2-GDNF and fetal ventral mesencephalon in MPTP monkeys
As before (Elsworth et al., 2000), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride
(MPTP; Sigma-Aldrich Corp., St. Louis, MO) was administered by intramuscular injection 4
times over 5 days, so that the total dose of MPTP given to each monkey was 2.0 mg/kg. The
behavior of each monkey was rated by observers, blinded to experimental conditions, twice
daily, 5 days a week, for the first month after MPTP treatment, to classify severity of
parkinsonian symptoms (Taylor et al., 1994; Taylor et al., 1997). The four MPTP-treated
monkeys used in this part of the study were asymptomatic or mildly symptomatic. MPTP-
treated monkeys in these categories have substantial striatal dopamine depletion (>50%,
Elsworth et al., 2000), which is relevant as outgrowth of grafted fetal dopamine neuron is
inhibited in the non-lesioned striatum (Doucet et al., 1990). Two months after MPTP treatment
(75 ± 1 days) implantation of embryonic ventral mesencephalon (VM) with or without AAV2-
GDNF was performed.
Three monkeys each received bilateral solid tissue grafts of VM in the head of the caudate
nucleus with a 10-microliter injection of either AAV2-GDNF (left) or saline (right) 4 mm
anterior to the VM deposit in the caudate nucleus. Implants were made by using stereotactic
surgery with a direct vertical approach (Sladek et al., 1995). Appropriate donor tissue for
implantation was derived from embryonic monkeys and identified by ultrasonography of
pregnant monkeys (crown-rump length 16–20 mm, estimated fetal age 45–48 days). VM was
dissected, then divided along the midline, and dissected further to isolate the developing DA
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neurons of the substantia nigra. The 2 dissected halves of a donor VM were transplanted to the
left and right caudate nucleus of one host monkey (Sladek et al., 1995). One additional MPTP-
treated monkey received a unilateral graft of half a fetal VM (crown-rump length 17 mm,
estimated fetal age 46 days) with an adjacent AAV2-GDNF injection, of the same volume from
the same vector stock at the same coordinates as the other monkeys. Six months after
transplantation (187 ± 1 days) animals were euthanized and brains fixed, as described above.
Vibratome sections through the caudate nucleus were cut in a sagittal plane and stained for
tyrosine hydroxylase (TH)-ir, in order to make stereological estimates of grafted TH-ir cells
and grafted TH-ir fiber density. Every fourth section was double-labeled for GDNF- and TH-
immunoreactivity, using goat anti-GDNF (BAF-212 at 1:250, R&D Systems, Minneapolis,
MN) and mouse anti-TH (MAB318 at 1:1000, Chemicon, Temecula, CA). GDNF-
immunoreactivity was visualized using biotinylated horse anti-goat IgG (BA-9500 at 1:250,
Vector Laboratories, Burlingame, CA), and the ABC technique with DAB as chromagen. TH-
immunoreactivity was visualized using biotinylated horse anti-mouse IgG (BA-2000 at 1:200,
Vector Laboratories), and the ABC technique with nickel-intensified DAB as chromogen.
Quantification comprised unbiased stereological counts of TH-ir in the caudate nucleus. These
measures were made using StereoInvestigator 7 software (MicroBrightField Inc.).
Results
Time-course of GDNF expression following AAV2-GDNF injection
The number of cells expressing GDNF in the caudate nucleus did not change significantly
between 1 and 6 months after injection of AAV2-GDNF (Fig. 2). The mean number of cells
(± S.E.) expressing GDNF in response to the one injection of AAV2-GDNF was 27919 ± 6158.
In addition, the volume of the caudate nucleus occupied by diffuse staining for GDNF-ir did
not diminish over the time period examined (Fig. 2). The mean volume occupied by elevated
GDNF staining was 50 ± 6 mm3.
Effect of AAV2-GDNF injection on survival and outgrowth of grafted fetal dopamine neurons
The number of surviving grafted TH-ir cells in each caudate nucleus was counted in monkeys
that received half of the donor VM in each caudate nucleus and AAV-2-GDNF in only one
caudate nucleus. The side of the brain with AAV2-GDNF consistently contained more
surviving TH+ cells. The increase ranged from 2- to 10-fold; a mean 4-fold greater number
TH-ir neurons were in the graft on the side of the brain with AAV2-GDNF compared with the
contralateral side (Figs. 3 and 4).
The effect of GDNF on outgrowth of grafted fetal DA neurons was measured by comparing
TH-ir fiber densities on the side of the graft facing the AAV2-GDNF (or vehicle) implant with
the TH-ir fiber density on the non-implanted side of the graft. This estimate revealed that the
TH-ir fiber density was 2–3 fold higher adjacent to the AAV2-GDNF implant (Fig. 5 and 6).
The preferential outgrowth of TH+ toward the AAV2-GDNF injection site also was observed
in the monkey that received a unilateral graft of half a fetal VM and an AAV2-GDNF injection.
TH staining intensity in this additional monkey was 2.7 times higher on the side facing the
vector (rostral to the graft), compared with the side opposite the vector implant site (caudal to
the graft), consistent with the data obtained in monkeys with bilateral grafts. As expected,
inclusion of the unilaterally grafted monkey in the statistical analysis of TH+ outgrowth did
not alter the conclusion that AAV2-GDNF enhanced grafted TH+ fiber outgrowth (t (5)=9.0,
p<0.0005).
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Our study of the time-course of GDNF overexpression in normal monkeys revealed that there
was no decrease in expression between 1 and 6 months following injection of AAV2-GDNF
in the caudate nucleus of monkeys. This outcome was in line with our expectations, based on
the absence of toxicity, low immunogenicity and sustained transgene expression of AAV
vectors using the chicken β-actin/cytomegalovirus (Tenenbaum et al., 2004). These results
showing sustained overexpression of GDNF in normal monkeys striatum justified an
investigation of the potential of AAV2-GDNF to enhance the survival and outgrowth of grafted
fetal DA neurons in MPTP-treated monkeys in a relatively long-term study. In fact, the volume
of striatum occupied by transduced cells in the monkey was larger than predicted by rodent
studies, in which rAAV serotype 2 vectors have delivered genes only to a restricted region
surrounding the injection needle (Paterna et al., 2004; Taymans et al., 2007). While this
apparent difference in distribution of GDNF may be due to species or methodological
differences, the observation of substantial spread of GDNF promised adequate exposure of the
graft to GDNF. Intrastriatal injection AAV2-GDNF was observed to increase markedly the
survival and outgrowth of co-grafted fetal TH-positive cells in the striatum of MPTP-treated
monkeys when examined 6 months after implantation. Thus, these data suggest that
supplementing intrastriatal fetal VM grafts with in vivo injections of viral vector delivering
the GDNF gene may decrease the number of VM grafts necessary to re-supply the host striatum
with adequate levels of DA. This would be a significant achievement, as the use of eight donors
for one human host (Hauser et al., 1999; Olanow et al., 2003) is an obstacle to neural grafting
as a treatment option for Parkinson’s disease.
In addition to striatal cells expressing GDNF, we noticed other apparently non-cellular
structures that stained for GDNF. These appeared in the vicinity and beyond the area of diffuse
GDNF staining. Their appearance was not dependent on the presence of fetal tissue, as they
appeared in brains injected with AAV2-GDNF vector alone, and in brains from our studies
injected with other vectors carrying the GDNF gene, specifically AAV5 or equine infectious
anemia virus, but not in brains injected with AAV2 vector harboring the gene for green
fluorescent protein. In the time course study (Fig. 2) their occurrence was more prevalent at
later time points than at one month. While we do not have a definitive identification of these
structures, it is possible that they are associated with extracellular matrix complexes (Lapchak
et al., 1998;Ruoslahti, 1996;Venstrom and Reichardt, 1993).
There have been indications from rodent experiments that overexpression of GDNF using a
recombinant lentiviral vector can lead eventually to down-regulation of TH (see Introduction
and Georgievska et al., 2004a). While we do not have a time-course to suggest whether the
level of TH expression is altered over the course of 6 months studied, our data showing a robust
increase in TH+ cell survival and TH+ fiber outgrowth suggests that a down-regulation did not
occur in our study in monkeys using a recombinant AAV. There are several plausible reasons
for a more persistent beneficial effect of GDNF on TH in grafted fetal DA neurons in the
monkey compared to the rat. As the development of primate brain is extended over a longer
period of time than in rodents, it may be that TH in grafted DA neurons will be down-regulated
in the monkey, if exposed to elevated GDNF levels for longer than the 6 months studied,
possibly when the grafted neurons have reached a stage of maturity when they no longer would
normally require high levels of GDNF. Alternatively, since the relationship between GDNF
concentration, time of GDNF exposure and TH activity has not been defined, it may be that
down-regulation of the enzyme will not occur over time if exposure to GDNF does not exceed
a certain threshold. In addition, as TH in primate brain exists in multiple isoforms (Haycock,
2002) which may be differentially regulated (Lehmann et al., 2006), it is feasible that the effect
of high GDNF concentrations over time will be different in the primate and rodent brain.
Finally, the different parkinsonian models used here and in the rodent study (Georgievska et
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al., 2004a) may have a bearing on the effects of GDNF on TH. So, while no evidence of TH
down-regulation was seen in the current study, further work will be necessary to determine
whether, and under what conditions, this may occur in primate brain.
Some parkinsonian patients that received fetal VM grafts in recent clinical trials developed
off-medication dyskinesias or graft-induced dyskinesias (GID) (Freed et al., 2001; Hagell et
al., 2002; Olanow et al., 2003). The proportion of patients in these 3 studies with GID severe
enough to constitute clinical therapeutic problems has been estimated to be between 7 and 15%
(Hagell and Cenci, 2005). There is yet no agreement on the cause(s) of this side-effect. Possible
explanations have been based on the cellular composition of the graft, the immune response,
and the integration of graft and host cells, and damage from the transplantation procedure
(Hagell and Cenci, 2005). A leading theory is that GID are due to an incomplete and uneven
striatal DA reinnervation by fetal grafts (Carlsson et al., 2006; Hagell and Cenci, 2005; Steece-
Collier et al., 2003). If this latter suggestion is correct, then targeted overexpression of GDNF
in combination with fetal grafts in the striatum in Parkinson’s disease may lessen the propensity
for GID, as this treatment was observed to increase cell survival and outgrowth of donor DA
neurons in the MPTP-treated monkey. While a possible differential effect of GDNF on
outgrowth of A9 and A10 neurons needs to be investigated in vivo (Borgal et al., 2007), the
observed enhanced survival of grafted DA neurons by GDNF indicates that this combination
strategy would enable fewer VM donors to be used to re-supply the parkinsonian striatum with
adequate DA levels. The significance of reducing the number of donors required for one host
brain in the transplantation treatment for Parkinson’s disease is that it would lessen both the
trauma of the surgery and the risk of a deleterious immune response (Hagell and Cenci,
2005). Thus, there are several theoretical arguments that favor the use of fetal VM grafts
together with a viral vector carrying the GDNF gene to lessen the susceptibility for development
of GID in Parkinson’s disease.
Another advantage to the use of viral vector delivered GDNF to support fetal grafts in
Parkinson’s disease is that GDNF by itself may provide protection of the ongoing degenerating
host DA neurons. In fact, clinical trials have been conducted to examine the effect of brain
infusion of GDNF on clinical outcome in patients with Parkinson’s disease. While some
encouraging data emerged, side-effects were noted, which may have resulted from the high
concentrations of GDNF delivered locally (Eslamboli, 2005; Kirik et al., 2004; Sherer et al.,
2006). The use of viral vectors to deliver GDNF in a stable, and potentially a regulated manner,
offers a more promising approach to protect remaining DA neurons in Parkinson’s disease than
direct infusions of GDNF (Kordower, 2003; McBride and Kordower, 2002). Thus, in patients
with Parkinson’s disease who have received fetal VM grafts, viral vector-mediated over-
expression of GDNF might be expected to enhance the benefit of the transplant, in addition to
retarding the neurodegeneration of the host nigrostriatal DA system.
In summary, the present studies have demonstrated a prolonged overexpression of GDNF in
monkey brain following intrastriatal injection of an AAV2-GDNF, and that co-implantation
of this viral vector in the vicinity of an intrastriatal fetal VM graft in the MPTP-treated monkey
led to the increased survival and outgrowth of TH+ neurons. The use of viral vectors to
overexpress GDNF, or other neurotrophic or neurotropic factors, in localized regions of the
brain may allow neural grafting to become a viable treatment strategy for Parkinson’s disease.
The beneficial effects of GDNF delivered by a viral vector reported here for fetal DA neurons
also could be applied to tailor the fate of stem cells transplanted to the parkinsonian brain.
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The AAV2 vector contained the human GDNF cDNA, driven by a chicken beta-actin promoter
with a cytomegalovirus immediate-early enhancer (CBA promoter), and a SV40
polyadenylation site, flanked by AAV2 inverted terminal repeats.
Elsworth et al. Page 11














Sustained GDNF expression in caudate nucleus following injection of AAV2-GDNF. No
significant change in mean number of GDNF-containing cells or mean volume of GDNF
immunoreactivity for up to 6 months in normal monkeys (4 monkeys at 1 month, 3 monkeys
each at 3 and 6 months). Error bars show standard error of the mean.
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AAV2-GDNF increases grafted TH+ cell survival. The 2 halves of a fetal VM were implanted
on opposite sides of the brain in the caudate nucleus of 3 MPTP-treated monkeys. One caudate
nucleus also was injected with AAV2-GDNF anterior to the tissue graft. The effect of AAV2-
GDNF on the survival of grafted TH+ neurons was statistically significant (paired t-test; t(2)
=7.2, p<0.02). Bars represent mean ± standard error of the mean.
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Greater number of grafted TH-stained cells is seen in the side of the brain injected with AAV2-
GDNF. Each caudate nucleus received one of the halves of a fetal VM, while only one side
was treated with AAV2-GDNF. The panels show the 2 caudate nuclei of the same brain (a,
graft only; b, graft plus AAV2-GDNF). Some clusters of grafted TH-stained neurons survived
in the absence of AAV2-GDNF (arrows). However, a more extensive pattern of TH-positive
fiber outgrowth was seen on the side that received the vector (VS), and the neuropil of this
graft showed a substantially higher TH fiber density. Scale bar is 500 μm.
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AAV2-GDNF increases grafted TH+ cell outgrowth. The effect of AAV2-GDNF on the
outgrowth of grafted TH+ neurons was determined by comparing the ratio of the TH staining
intensity on the side facing the AAV2-GDNF injection (rostral) with the side facing away from
the vector (caudal). To control for rostral-caudal differences in TH density, the same ratio was
derived for the rostral and caudal regions of fetal grafts that received a saline injection instead
of the vector. A significantly greater TH staining ratio density was seen on the AAV2-GDNF
injected side (paired t-test; t(2)=6.0, p<0.05).
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Outgrowth of fetal TH+ fibers (black) from a graft (GR) is preferentially directed (A vs. B)
toward the region of GDNF staining (orange) associated with AAV2-GDNF implant (arrows).
Scale bars: main figure 500μm, A and B 250μm.
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